Prediction and prevention of preeclampsia

Hypertension in Pregnancy

Volumn 28, Issue 2, 2009, Pages 138-155

  Briceo Prez, Carlos ^a   Briceo Sanabria, Liliana ^b   Vigil De Gracia, Paulino ^c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b Amado Clinic   (Venezuela)

^c Hospital Complex Arnulfo Arias Madrid Social Security   (Panama)

Author keywords

Antioxidant; Aspirin; Calcium; Prediction; Preeclampsia; Prevention; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM; CARDIOLIPIN ANTIBODY; CHORIONIC GONADOTROPIN BETA SUBUNIT; FISH OIL; FOLIC ACID; HEPARIN; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; LYCOPENE; MAGNESIUM; MELATONIN; NICOTINE; NITRIC OXIDE; OMEGA 3 FATTY ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE; SELENIUM; SODIUM CHLORIDE; UBIDECARENONE; VASCULOTROPIN RECEPTOR 1; ZINC;

ARTICLE; CALCIUM INTAKE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIET; DIET THERAPY; DOPPLER ECHOGRAPHY; EXERCISE; GARLIC; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MATERNAL MORTALITY; NUTRITIONAL ASSESSMENT; OBESITY; PERINATAL MORBIDITY; PRACTICE GUIDELINE; PREDICTION; PREECLAMPSIA; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; PRIMARY PREVENTION; REST; RISK FACTOR; SALT INTAKE; SECONDARY PREVENTION; SODIUM RESTRICTION; VITAMIN SUPPLEMENTATION; FEMALE; PREDICTION AND FORECASTING; REVIEW;

FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY;

EID: 70149102881     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641950802022384     Document Type: Article

References (47)

1. Vigil-De Gracia P, Montufar-Rueda C, Ruiz J. Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks' gestation. Eur J Obstet Gynecol Reprod Biol 2003; 107:24-27.
2. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek J, Tem de Mena F, Lopez J. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol 2006; 128:157-162. (Pubitemid 44322020)
3. Sibai B, Dekker G, Kucferminc M. Preeclampsia. Lancet 2005; 365:785-799.
4. National high blood pressure education program working group on high blood pressure in pregnancy. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183:S1-S22.
5. Dekker G, Sibai B. Primary, secondary and tertiary prevention of preeclampsia. Lancet 2001; 357:209-215.
6. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening test for preeclampsia. Obstet Gynecol 2004; 104:1367-1391.
7. Farag K, Hassan I, Ledger W. Prediction of preeclampsia: can it be achieved? Obstet Gynecol Surv 2004; 59:464-482.
8. Helewa M, Burrow R, Smith J, Williams K, Brain P, Rabkin S. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. Can Med Assoc J 1997; 157:715-725.
9. American College of Obstetricians and Gynecologist. Diagnosis and management of preeclampsia and eclampsia. Practice Bulletin. Number 33. Obstet Gynecol 2002; 99:159-167.
10. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197:35.e1-35.e7.
11. Levine R, Lam C, Qian C, Yu K, Maynard S, Sachs B et al. Soluble endoglin, a novel circulating anti-angiogenic factor in preeclampsia. N Engl J Med 2006; 355:992-1005.
12. Salahuddin S, Lee Y, Vadnais M, Sachs B, Karumanchi A, Lim K. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197:28.e1-28.e6.
13. Levine R, Maynard S, Qian C, Lim K, England L, Yu K, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683. (Pubitemid 38364626)
14. Thadhani R, Mutter W, Wolf M, Levine R, Taylor R, Sukhatme V, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89:770-775.
15. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194:551-556.
16. Crispi F, Domínguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195:201-207.
17. Vatten L, Eskild A, Nilsen T, Jeansson S, Jenum P, Staff A. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196: 239.e1-239.e6.
18. Chappell L, Seed P, Briley A, Kelly F, Hunt B, Charnock-Jones D, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187:127-136.
19. Aquilina J, Thompson O, Thilaganathan B, Harrington K. Improved early prediction of preeclampsia by combining second trimester maternal serum inhibin-A and uterine artery Doppler. Ultrasound Obstet Gynecol 2001; 17:477-484.
20. Duley L, Meher S, Abalos E. Management of preeclampsia. BMJ 2006; 332:463-468.
21. Sibai B. Biomarkers for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol 2007; 197:1-2.
22. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C et al. The preeclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330;576-580.
23. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalization for hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 1. 2006. Oxford: Update Software.
24. Meher S, Duley L. Exercise or other physical activity for preventing preeclampsia and its complications (Cochrane Review). In: The Cochrane Library, Issue 2. 2006. Oxford: Update Software.
25. Hofmeyr G, Atallah A, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane Review). In: The Cochrane Library, Issue 3. 2006. Oxford: Update Software.
26. Levine R, Hauth J, Curet L. Trial of calcium to prevent preeclampsia. N Engl J Med 1997; 337:69-76.
27. Villar J, Andel-Aleem H, Merialdi M, Mathai M, Ali M, Zavaleta N, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006; 194:639-649.
28. Hofmeyr G, Duley L, Atallah A. Dietary calcium supplementation for prevention of preeclampsia and related problems: a systematic review and commentary. Br J Obstet Gynecol 2007; 114:933-943.
29. Rumbold A, Crowther C, Haslam R, Dekker G, Robinson J. Vitamins C and E and the risks of preeclampsia and perinatal complications. ACTS Study Group. N Engl J Med 2006; 354:1796-1806.
30. Rumbold A, Duley L, Crowther C, Haslam R. Antioxidants for preventing preeclampsia (Cochrane Review). In: The Cochrane Library, Issue 1. 2006. Oxford: Update Software.
31. Poston L, Briley A, Seed P, Kelly F, Shennan A. Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomized placebo controlled trial. Lancet 2006; 367:1145-1154.
32. Polyzos N, Mauri D, Tsappi M, Tzioras S, Kamposioras K, Cotinovis I et al. Combined vitamin C and E supplementation during pregnancy for preeclampsia prevention: a systematic review. Obstet Gynecol Surv 2007; 62:202-206.
33. Rouse D. Vitamins C and E and the risks of preeclampsia and perinatal complications. Obstet Gynecol Surv 2006; 61: 619-620.
34. Spinnato J, Livinston J. Prevention of preeclampsia with antioxidants: evidence from randomized trials. Clin Obstet Gynecol 2005; 48:416-429.
35. Villar J, Abalos E, Nardin J, Merialdi M, Carroli G. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 2004; 24:607-615.
36. Villar J, Merialdi M, Metin-Gülmezoglu A, Abalos E, Carroli G, Kulier R et al. Nutritional interventions during pregnancy for the prevention or treatment of maternal morbidity and preterm delivery: an overview of randomized controlled trials. J Nutr 2003; 133:1606S-1625S. (Pubitemid 36548666)
37. Olsen S, Secher N, Tabor A, Weber T, Walter J, Gluud C. Randomized clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. Br J Obstet Gynecol 2000; 107:382-395.
38. Duley L, Henderson-Smart D. Reduced salt intake compared to normal dietary salt or high intake in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 1. 2006. Oxford: Update Software.
39. Kramer M, Kakuma R. Energy and protein intake in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 3. 2007. Oxford: Update Software.
40. Frederick I, Willimas M, Dashow E, Kestin M, Zhang C, Leisenring W. Dietary fiber, potassium magnesium and calcium in relation to the risk of preeclampsia. J Reprod Med 2005; 50:332-344.
41. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan K. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101:1319-1332.
42. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet agents for preventing preeclampsia and its complications. (Cochrane Review). In: The Cochrane Library, Issue 1. 2006. Oxford: Update Software.
43. Ruano R, Fontes R, Zugaib M. Prevention of preeclampsia with low dose aspirin: a systematic review and meta-analysis of the main randomized controlled trials. Clinics 2005; 60:407-414.
44. Askie L, Duley L, Henderson-Smart D, Steward L, on behalf of the PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791-1798.
45. Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias (Cochrane Review). In: The Cochrane Library, Issue 1. 2006. Oxford: Update Software.
46. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchioni M et al. Low molecular weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensine converting enzyme DD women. Hypertension 2005; 45:86-91.
47. Rouse D. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Obstet Gynecol Surv 2007; 62: 697-699.